The present invention involves the identification of new polypeptides and variants of type 3 vascular-3 protein (ANGPTL3), which have better drug properties, such as being more stable, more protected and enzymatically degraded than wild ANGPTL3. Pharmaceutical ingredients and methods for the treatment of joint injury or joint injury, and methods for improving or preventing mammalian arthritis, joint injury or joint injury are also provided. Therefore,The peptide of antiprotein includes a series of amino acids with amino acid sequence characteristics of at least 95% or 96%.ninety-seven percentninety-eight percent99% or 100% amino acid sequence. Select a series of amino acids from any one or more sequences in Table 1, and further explain in this document. The modified peptide in Table 1 includes an amino acid, which is a polar amino acid not belonging to K or R. according to the full length peptide ANGPTL3 sequence, it is determined as 423, SEQ ID No.1. In some results, the amino acid is at 423 position, which is determined according to section Q or s of ID: 1 in some results,As shown in ID: 1, in case 423, the amino acid is Q in some cases, and in case 423 isLa presente invención se refiere a la identificación de nuevas variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (ANGPTL3) que tienen propiedades farmacéuticas mejoradas, por ejemplo, son más estables, menos susceptibles a la proteólisis y degradación enzimática que ANGPTL3 de tipo salvaje. También se proporcionan composiciones farmacéuticas y métodos para el tratamiento del daño articular o lesiones articulares, y los métodos para mejorar o prevenir artritis, daño en articulaciones o lesión de articulaciones en un mamífero. Por lo tanto, se proporcionan polipéptidos resistentes a la proteasa que comprenden una secuencia de aminoácidos que tiene al menos 95% de identidad de secuencia de aminoácidos, o al menos 96%, 97%, 98%, 99% o 100% de identidad de secuencia de aminoácidos con una secuencia de ami
